BiondVax Pharmaceuticals Ltd is a biopharmaceutical company dedicated to developing, manufacturing, and distributing groundbreaking immunotherapeutic products for the treatment of infectious and autoimmune diseases. With a focus on innovation, BiondVax has conducted a range of clinical trials, including a comprehensive Phase 3 trial involving 12,400 participants across seven countries. In addition, the company has established a state-of-the-art manufacturing facility for biopharmaceutical products.

Led by a team of seasoned leaders in the pharmaceutical industry, BiondVax strives to create a diverse portfolio of commercially viable products and platforms. Their pioneering approach begins with a unique nanosized antibody (NanoAb) pipeline. BiondVax’s exceptional team comprises scientists, technicians, researchers, and administrative staff.

Their cutting-edge GMP facility in Israel serves as a hub for laboratories, production facilities, and offices. By leveraging their expertise and state-of-the-art infrastructure, BiondVax is committed to advancing the field of immunotherapy and improving the lives of patients worldwide